Lilly’s Patient-Friendly Ready-to-Use once weekly GLP-1 agonist Trulicity approved in the US
Twitter Summary: FDA approves Trulicity for #T2D, 1st ready-to-use once-weekly GLP-1 agonist in the US, with a patient-friendly “auto-injector” – launch for later this year
On September 18, the FDA approved Eli Lilly’s Trulicity (dulaglutide) for type 2 diabetes, making it the third once-weekly injectable GLP-1 agonist approved in the US after GlaxoSmithKline’s Tanzeum (albiglutide) and AstraZeneca’s Bydureon (exenatide). Eli Lilly plans to launch Trulicity later this year, available in both .75 mg and 1.5 mg doses. It is not recommended for anyone with a history of pancreatitis or severe gastrointestinal problems (e.g., gastroparesis). For more information on Trulicity’s side effects, please see its approved drug label. There is no word yet on reimbursement or pricing information for Trulicity.
Trulicity has the potential to transform the conversation that people with type 2 diabetes have with their providers when oral therapies are no longer enough to control their blood glucose. Currently, when reaching that point, many people choose to begin basal insulin. Lilly studied Trulicity in comparison with the basal insulin Lantus (insulin glargine), and found that Trulicity 1.5 mg provided greater reductions in A1c, weight loss benefits, and less hypoglycemia. Trulicity is also the first GLP-1 agonist to show similar efficacy to that of the once daily GLP-1 agonist Victoza (Novo Nordisk’s liraglutide). With such compelling clinical data and its remarkable ease of use, we can’t help but wonder if Trulicity could be used even earlier in the course of type 2 diabetes than other drugs in this class have been used until now. GLP-1 agonists provide important benefits to patients – strong glucose lowering with less hypoglycemia and weight gain – and we are glad that Trulicity will make this drug easier for people to take. –MV/AJW